Cerebrospinal fluid peptides as potential parkinson disease biomarkers: A staged pipeline for discovery and validation

Molecular and Cellular Proteomics

Volumn 14, Issue 3, 2015, Pages 544-555

  Shi, Min ^a   Movius, James ^a   Dator, Romel ^a   Aro, Patrick ^a   Zhao, Yanchun ^a   Pan, Catherine ^a   Lin, Xiangmin ^a,b   Bammler, Theo K ^c   Stewart, Tessandra ^a   Zabetian, Cyrus P ^a,d   Peskind, Elaine R ^a,d   Hu, Shu Ching ^a,d   Quinn, Joseph F ^e   Galasko, Douglas R ^f   Zhang, Jing ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b FUJIAN AGRICULTURE AND FORESTRY UNIVERSITY   (China)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID LIKE PROTEIN 1; AMYLOID PROTEIN; ANTITHROMBIN III; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; BIOLOGICAL MARKER; CADHERIN 8; CERULOPLASMIN; COMPLEMENT COMPONENT C3; EPHRIN RECEPTOR A4; KALLIKREIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MACROPHAGE COLONY STIMULATING FACTOR 1 RECEPTOR; NTITHROMBIN III; PEPTIDE DERIVATIVE; PEROXIREDOXIN 6; PROSAPOSIN RECEPTOR GPR37; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UBIQUITIN 40S RIBOSOMAL PROTEIN S27A; UNCLASSIFIED DRUG; PEPTIDE;

ADULT; AGE; AGED; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ARTICLE; BIOINFORMATICS; CLINICAL OBSERVATION; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEOMICS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEX RATIO; UNIFIED PARKINSON DISEASE RATING SCALE; VALIDATION STUDY; CEREBROSPINAL FLUID; CLINICAL TRIAL; MASS SPECTROMETRY; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOMARKERS; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PARKINSON DISEASE; PEPTIDES; PROTEOMICS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 84924289947     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M114.040576     Document Type: Article

References (58)

1. Lang, A. E., and Lozano, A. M. (1998) Parkinson's disease. First of two parts. N. Engl. J. Med. 339, 1044-1053
2. Thomas, B., and Beal, M. F. (2007) Parkinson's disease. Hum. Mol. Genet. 16 Spec No. 2, R183-R194
3. Jankovic, J. (2008) Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79, 368-376
4. Tolosa, E., Wenning, G., and Poewe, W. (2006) The diagnosis of Parkinson's disease. Lancet Neurol. 5, 75-86
5. Schapira, A. H. (2013) Recent developments in biomarkers in Parkinson disease. Curr. Opin. Neurol. 26, 395-400
6. O'Keeffe, G. C., Michell, A. W., and Barker, R. A. (2009) Biomarkers in Huntington's and Parkinson's disease. Ann. N.Y. Acad. Sci. 1180, 97-110
7. Booij, J., and Berendse, H. W. (2011) Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway. J. Neurol. Sci. 310, 40-43
8. Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., Montine, T. J., Hancock, A. M., Hwang, H., Pan, C., Bradner, J., Kang, U. J., Jensen, P. H., and Zhang, J. (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713-726
9. Mollenhauer, B., Locascio, J. J., Schulz-Schaeffer, W., Sixel-Döring, F., Trenkwalder, C., and Schlossmacher, M. G. (2011) alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230-240
10. Kang, J. H., Irwin, D. J., Chen-Plotkin, A. S., Siderowf, A., Caspell, C., Coffey, C. S., Waligorska, T., Taylor, P., Pan, S., Frasier, M., Marek, K., Kieburtz, K., Jennings, D., Simuni, T., Tanner, C. M., Singleton, A., Toga, A. W., Chowdhury, S., Mollenhauer, B., Trojanowski, J. Q., and Shaw, L. M. (2013) Association of cerebrospinal fluid beta-amyloid 1-42, t-tau, p-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 70, 1277-1287
11. Shi, M., Bradner, J., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Kim, H. M., Leverenz, J. B., Montine, T. J., Ginghina, C., Kang, U. J., Cain, K. C., Wang, Y., Aasly, J., Goldstein, D., and Zhang, J. (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 69, 570-580
12. Hall, S., Ohrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Hakan, W., Decraemer, H., Nagga, K., Minthon, L., Londos, E., Vanmechelen, E., Holmberg, B., Zetterberg, H., Blennow, K., and Hansson, O. (2012) Accuracy of a panel of five cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol. 69, 1445-1452
13. Mattsson, N., Blennow, K., and Zetterberg, H. (2010) Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin. Chem. Lab. Med. 48, 603-607
14. Mattsson, N., Andreasson, U., Persson, S., Carrillo, M. C., Collins, S., Chalbot, S., Cutler, N., Dufour-Rainfray, D., Fagan, A. M., Heegaard, N. H., Robin Hsiung, G. Y., Hyman, B., Iqbal, K., Lachno, D. R., Lleo, A., Lewczuk, P., Molinuevo, J. L., Parchi, P., Regeniter, A., Rissman, R., Rosenmann, H., Sancesario, G., Schroder, J., Shaw, L. M., Teunissen, C. E., Trojanowski, J. Q., Vanderstichele, H., Vandijck, M., Verbeek, M. M., Zetterberg, H., Blennow, K., and Kaser, S. A. (2013) CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 9, 251-261
15. Jaffe, J. D., Keshishian, H., Chang, B., Addona, T. A., Gillette, M. A., and Carr, S. A. (2008) Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification. Mol. Cell. Proteomics 7, 1952-1962
16. Whiteaker, J. R., Lin, C., Kennedy, J., Hou, L., Trute, M., Sokal, I., Yan, P., Schoenherr, R. M., Zhao, L., Voytovich, U. J., Kelly-Spratt, K. S., Krasnoselsky, A., Gafken, P. R., Hogan, J. M., Jones, L. A., Wang, P., Amon, L., Chodosh, L. A., Nelson, P. S., McIntosh, M. W., Kemp, C. J., and Paulovich, A. G. (2011) A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat. Biotechnol. 29, 625-634
17. Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J., Mani, D. R., Bunk, D. M., Spiegelman, C. H., Zimmerman, L. J., Ham, A. J., Keshishian, H., Hall, S. C., Allen, S., Blackman, R. K., Borchers, C. H., Buck, C., Cardasis, H. L., Cusack, M. P., Dodder, N. G., Gibson, B. W., Held, J. M., Hiltke, T., Jackson, A., Johansen, E. B., Kinsinger, C. R., Li, J., Mesri, M., Neubert, T. A., Niles, R. K., Pulsipher, T. C., Ransohoff, D., Rodriguez, H., Rudnick, P. A., Smith, D., Tabb, D. L., Tegeler, T. J., Variyath, A. M., Vega-Montoto, L. J., Wahlander, A., Waldemarson, S., Wang, M., Whiteaker, J. R., Zhao, L., Anderson, N. L., Fisher, S. J., Liebler, D. C., Paulovich, A. G., Regnier, F. E., Tempst, P., and Carr, S. A. (2009) Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 27, 633-641
18. Selevsek, N., Matondo, M., Sanchez Carbayo, M., Aebersold, R., and Domon, B. (2011) Systematic quantification of peptides/proteins in urine using selected reaction monitoring. Proteomics 11, 1135-1147
19. Abdi, F., Quinn, J. F., Jankovic, J., McIntosh, M., Leverenz, J. B., Peskind, E., Nixon, R., Nutt, J., Chung, K., Zabetian, C., Samii, A., Lin, M., Hattan, S., Pan, C., Wang, Y., Jin, J., Zhu, D., Li, G. J., Liu, Y., Waichunas, D., Montine, T. J., and Zhang, J. (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 9, 293-348
20. Jin, J., Hulette, C., Wang, Y., Zhang, T., Pan, C., Wadhwa, R., and Zhang, J. (2006) Proteomic identification of a stress protein, mortalin/mthsp70/ GRP75: relevance to Parkinson disease. Mol. Cell. Proteomics 5, 1193-1204
21. Kitsou, E., Pan, S., Zhang, J., Shi, M., Zabeti, A., Dickson, D. W., Albin, R., Gearing, M., Kashima, D. T., Wang, Y., Beyer, R. P., Zhou, Y., Pan, C., Caudle, W. M., and Zhang, J. (2008) Identification of proteins in human substantia nigra. Proteomics Clin. Appl. 2, 776-782
22. Pan, S., Shi, M., Jin, J., Albin, R. L., Lieberman, A., Gearing, M., Lin, B., Pan, C., Yan, X., Kashima, D. T., and Zhang, J. (2007) Proteomics identification of proteins in human cortex using multidimensional separations and MALDI tandem mass spectrometer. Mol. Cell. Proteomics 6, 1818-1823
23. Shi, M., Jin, J., Wang, Y., Beyer, R. P., Kitsou, E., Albin, R. L., Gearing, M., Pan, C., and Zhang, J. (2008) Mortalin: a protein associated with progression of Parkinson disease? J. Neuropathol. Exp. Neurol. 67, 117-124
24. Shi, M., Bradner, J., Bammler, T. K., Eaton, D. L., Zhang, J., Ye, Z., Wilson, A. M., Montine, T. J., Pan, C., and Zhang, J. (2009) Identification of glutathione S-transferase pi as a protein involved in Parkinson disease progression. Am. J. Pathol. 175, 54-65
25. Hwang, H., Zhang, J., Chung, K. A., Leverenz, J. B., Zabetian, C. P., Peskind, E. R., Jankovic, J., Su, Z., Hancock, A. M., Pan, C., Montine, T. J., Pan, S., Nutt, J., Albin, R., Gearing, M., Beyer, R. P., Shi, M., and Zhang, J. (2010) Glycoproteomics in neurodegenerative diseases. Mass Spectrom. Rev. 29, 79-125
26. Wang, Y., Shi, M., Chung, K. A., Zabetian, C. P., Leverenz, J. B., Berg, D., Srulijes, K., Trojanowski, J. Q., Lee, V. M., Siderowf, A. D., Hurtig, H., Litvan, I., Schiess, M. C., Peskind, E. R., Masuda, M., Hasegawa, M., Lin, X., Pan, C., Galasko, D., Goldstein, D. S., Jensen, P. H., Yang, H., Cain, K. C., and Zhang, J. (2012) Phosphorylated alpha-synuclein in Parkinson's disease. Sci. Transl. Med. 4, 121ra120
27. Lin, X., Cook, T. J., Zabetian, C. P., Leverenz, J. B., Peskind, E. R., Hu, S. C., Cain, K. C., Pan, C., Edgar, J. S., Goodlett, D. R., Racette, B. A., Checkoway, H., Montine, T. J., Shi, M., and Zhang, J. (2012) DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci. Rep. 2, 954
28. MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M., Finney, G. L., Frewen, B., Kern, R., Tabb, D. L., Liebler, D. C., and MacCoss, M. J. (2010) Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966-968
29. Box, G. E. P., and Cox, D. R. (1964) An analysis of transformations. J. R. Stat. Soc. B. 26, 211-252
30. Ellington, A. A., Kullo, I. J., Bailey, K. R., and Klee, G. G. (2010) Antibodybased protein multiplex platforms: technical and operational challenges. Clin. Chem. 56, 186-193
31. Carecchio, M., and Comi, C. (2011) The role of osteopontin in neurodegenerative diseases. J. Alzheimers Dis. 25, 179-185
32. Iczkiewicz, J., Jackson, M. J., Smith, L. A., Rose, S., and Jenner, P. (2006) Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease. Brain Res. 1118, 239-250
33. Maetzler, W., Berg, D., Schalamberidze, N., Melms, A., Schott, K., Mueller, J. C., Liaw, L., Gasser, T., and Nitsch, C. (2007) Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol. Dis. 25, 473-482
34. Sun, Y., Yin, X. S., Guo, H., Han, R. K., He, R. D., and Chi, L. J. (2013) Elevated osteopontin levels in mild cognitive impairment and Alzheimer's disease. Mediators Inflamm. 2013:615745
35. Zlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., and Winkler, E. A. (2010) Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. J. Neurochem. 115, 1077-1089
36. Kanekiyo, T., Cirrito, J. R., Liu, C. C., Shinohara, M., Li, J., Schuler, D. R., Shinohara, M., Holtzman, D. M., and Bu, G. (2013) Neuronal clearance of amyloid-beta by endocytic receptor LRP1. J. Neurosci. 33, 19276-19283
37. Liu, Q., Trotter, J., Zhang, J., Peters, M. M., Cheng, H., Bao, J., Han, X., Weeber, E. J., and Bu, G. (2010) Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss, and neurodegeneration. J. Neurosci. 30, 17068-17078
38. Wilhelmus, M. M., Bol, J. G., Van Haastert, E. S., Rozemuller, A. J., Bu, G., Drukarch, B., and Hoozemans, J. J. (2011) Apolipoprotein E and LRP1 increase early in Parkinson's disease pathogenesis. Am. J. Pathol. 179, 2152-2156
39. Liu, Q., Zhang, J., Tran, H., Verbeek, M. M., Reiss, K., Estus, S., and Bu, G. (2009) LRP1 shedding in human brain: roles of ADAM10 and ADAM17. Mol. Neurodegener. 4, 17
40. Luo, J., Elwood, F., Britschgi, M., Villeda, S., Zhang, H., Ding, Z., Zhu, L., Alabsi, H., Getachew, R., Narasimhan, R., Wabl, R., Fainberg, N., James, M. L., Wong, G., Relton, J., Gambhir, S. S., Pollard, J. W., and Wyss-Coray, T. (2013) Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. J. Exp. Med. 210, 157-172
41. Erblich, B., Zhu, L., Etgen, A. M., Dobrenis, K., and Pollard, J. W. (2011) Absence of colony stimulation factor-1 receptor results in loss of microglia, disrupted brain development, and olfactory deficits. PLoS One 6, e26317
42. Van Hoecke, A., Schoonaert, L., Lemmens, R., Timmers, M., Staats, K. A., Laird, A. S., Peeters, E., Philips, T., Goris, A., Dubois, B., Andersen, P. M., Al-Chalabi, A., Thijs, V., Turnley, A. M., van Vught, P. W., Veldink, J. H., Hardiman, O., Van Den Bosch, L., Gonzalez-Perez, P., Van Damme, P., Brown, R. H., Jr., van den Berg, L. H., and Robberecht, W. (2012) EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat. Med. 18, 1418-1422
43. Klein, R. (2009) Bidirectional modulation of synaptic functions by Eph/ ephrin signaling. Nat. Neurosci. 12, 15-20
44. Fang, Q., Strand, A., Law, W., Faca, V. M., Fitzgibbon, M. P., Hamel, N., Houle, B., Liu, X., May, D. H., Poschmann, G., Roy, L., Stuhler, K., Ying, W., Zhang, J., Zheng, Z., Bergeron, J. J., Hanash, S., He, F., Leavitt, B. R., Meyer, H. E., Qian, X., and McIntosh, M. W. (2009) Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol. Cell. Proteomics 8, 451-466
45. Porter, J. F., Sharma, S., Wilson, D. L., Kappil, M. A., Hart, R. P., and Denhardt, D. T. (2005) Tissue inhibitor of metalloproteinases-1 stimulates gene expression in MDA-MB-435 human breast cancer cells by means of its ability to inhibit metalloproteinases. Breast Cancer Res. Treat. 94, 185-193
46. Kim, E. M., and Hwang, O. (2011) Role of matrix metalloproteinase-3 in neurodegeneration. J. Neurochem. 116, 22-32
47. Ashutosh, Chao, C., Borgmann, K., Brew, K., and Ghorpade, A. (2012) Tissue inhibitor of metalloproteinases-1 protects human neurons from staurosporine and HIV-1-induced apoptosis: mechanisms and relevance to HIV-1-associated dementia. Cell Death Dis. 3, e332
48. Bjerke, M., Zetterberg, H., Edman, A., Blennow, K., Wallin, A., and Andreasson, U. (2011) Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. J. Alzheimers Dis. 27, 665-676
49. Lorenzl, S., Albers, D. S., LeWitt, P. A., Chirichigno, J. W., Hilgenberg, S. L., Cudkowicz, M. E., and Beal, M. F. (2003) Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J. Neurol. Sci. 207, 71-76
50. Kim, Y. S., and Joh, T. H. (2012) Matrix Metalloproteinases, New Insights into the Understanding of Neurodegenerative Disorders. Biomol. Ther. 20, 133-143
51. Kim, T. W., Wu, K., Xu, J. L., McAuliffe, G., Tanzi, R. E., Wasco, W., and Black, I. B. (1995) Selective localization of amyloid precursor-like protein 1 in the cerebral cortex postsynaptic density. Brain Res. Mol. Brain Res. 32, 36-44
52. Guilarte, T. R., Burton, N. C., Verina, T., Prabhu, V. V., Becker, K. G., Syversen, T., and Schneider, J. S. (2008) Increased APLP1 expression and neurodegeneration in the frontal cortex of manganese-exposed non-human primates. J. Neurochem. 105, 1948-1959
53. Paliga, K., Peraus, G., Kreger, S., Durrwang, U., Hesse, L., Multhaup, G., Masters, C. L., Beyreuther, K., and Weidemann, A. (1997) Human amyloid precursor-like protein 1-cDNA cloning, ectopic expression in COS-7 cells, and identification of soluble forms in the cerebrospinal fluid. Eur. J. Biochem. 250, 354-363
54. Yanagida, K., Okochi, M., Tagami, S., Nakayama, T., Kodama, T. S., Nishitomi, K., Jiang, J., Mori, K., Tatsumi, S., Arai, T., Ikeuchi, T., Kasuga, K., Tokuda, T., Kondo, M., Ikeda, M., Deguchi, K., Kazui, H., Tanaka, T., Morihara, T., Hashimoto, R., Kudo, T., Steiner, H., Haass, C., Tsuchiya, K., Akiyama, H., Kuwano, R., and Takeda, M. (2009) The 28-amino acid form of an APLP1-derived Abeta-like peptide is a surrogate marker for Abeta42 production in the central nervous system. EMBO Mol. Med. 1, 223-235
55. Baker, S. G., Kramer, B. S., and Srivastava, S. (2002) Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med. Res. Methodol. 2, 4
56. Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., Macarthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., Nazar, M. D., Rich, S. A., Berlau, D. J., Peltz, C. B., Tan, M. T., Kawas, C. H., and Federoff, H. J. (2014) Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med., in press (doi: 10.1038/nm. 3466)
57. Beyer, K. (2006) Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. 112, 237-251
58. Wang, Y., Hancock, A. M., Bradner, J., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Kim, H. M., Leverenz, J. B., Montine, T. J., Ginghina, C., Edwards, K. L., Snapinn, K. W., Goldstein, D. S., Shi, M., and Zhang, J. (2011) Complement 3 and factor H in human cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease. Am. J. Pathol. 178, 1509-1516